Advertisement
  News   Nation  16 Sep 2020  Serum Institute of India gets DCGI nod to resume trial of Oxford Covid-19 vaccine

Serum Institute of India gets DCGI nod to resume trial of Oxford Covid-19 vaccine

ROZANA SPOKESMAN
Published Sep 16, 2020, 9:29 am IST
Updated Sep 16, 2020, 9:29 am IST
Drugs Controller General of India (DCGI) Dr V G Somani gave permission to Serum Institute of India to resume clinical trial of the Oxford
Covid-19 vaccine
 Covid-19 vaccine

New Delhi: Drugs Controller General of India (DCGI) Dr V G Somani gave permission to Serum Institute of India to resume clinical trial of the Oxford Covid-19 vaccine candidate in the country while revoking its earlier order of suspending any new recruitment for phase two and three trial.

The DCGI, however, put certain conditions like taking extra care during screening, providing additional information in informed consent and close monitoring for adverse events during follow-up of the study which have to be followed by Serum Institute of India (SII).

Covid-19 vaccineCovid-19 vaccineSII has also been asked to submit to the DCGI's office details of medication used in accordance with the protocol for management of adverse events.

The DCGI had on September 11 directed Serum Institute of India to suspend any new recruitment in the phase two and three clinical trial of the Oxford Covid-19 vaccine candidate till further orders in the backdrop of pharma giant AstraZeneca pausing the clinical trials in other countries because of an unexplained illness in a participant in the study.

On Saturday, British-Swedish biopharmaceutical giant AstraZeneca and the University of Oxford said clinical trials for their coronavirus vaccine have resumed in the UK after the Medicines Health Regulatory Authority's (MHRA) confirmed that the trials were safe.

Covid-19 vaccineCovid-19 vaccine

SII, which has partnered with AstraZeneca for manufacturing the vaccine candidate for Covid-19, on Tuesday submitted the recommendations of the Data and Safety Monitoring Board (DSMB), UK and DSMB, India, and requested for permission to restart enrolment in the clinical trial.

According to Tuesday's order issued by DCGI, the DSMB, UK, recommended that the investigators recommence all immunization in their clinical trials subject to certain conditions.

DSMB, India, also has recommended to continue the study and enroll the remaining participants in the clinical trial as per protocol subject to certain conditions.

Advertisement
Advertisement
Advertisement